Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

by Scott, Nicola , Peppercorn, Amanda , Shapiro, Adrienne E , Mogalian, Erik , Falci, Diego R , Cathcart, Andrea L , Crespo Casal, Manuel , Brinson, Cynthia , Aldinger, Melissa , Juarez, Erick , Alexander, Elizabeth , Gonzalez-Rojas, Yaneicy , Sarkis, Elias , Zheng, Hanzhe , Hebner, Christy M , Gupta, Anil , Moya, Jaynier , Free, Almena , Solis, Joel , Pang, Phillip S , Tipple, Craig , Sager, Jennifer

in Adult / Adverse events / Aged / Ambulatory Care / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antibodies, Neutralizing - adverse effects / Antibodies, Neutralizing - therapeutic use / Biotechnology / Chronic obstructive pulmonary disease / Coronavirus / Coronaviruses / COVID-19 / COVID-19 - drug therapy / Data collection / Death / Design / Diabetes / Disease Progression / Double-Blind Method / Early intervention / Female / Hospitalization - statistics & numerical data / Humans / Incidence / Infectious Disease / Infusions, Intravenous / Intention to Treat Analysis / International organizations / Kidney diseases / Length of Stay / Male / Middle Aged / Monoclonal antibodies / Pandemics / Patients / Placebos / Population / Risk assessment / Risk factors / Risk groups / SARS-CoV-2 - immunology / Severe acute respiratory syndrome coronavirus 2 / Statistical analysis

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

2021

Confirm

Do you wish to request the book?

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Scott, Nicola,

Peppercorn, Amanda,

Shapiro, Adrienne E,

Mogalian, Erik,

Falci, Diego R,

Cathcart, Andrea L,

Crespo Casal, Manuel,

Brinson, Cynthia,

Aldinger, Melissa,

Juarez, Erick,

Alexander, Elizabeth,

Gonzalez-Rojas, Yaneicy,

Sarkis, Elias,

Zheng, Hanzhe,

Hebner, Christy M,

Gupta, Anil,

Moya, Jaynier,

Free, Almena,

Solis, Joel,

Pang, Phillip S,

Tipple, Craig,

Sager, Jennifer

2021

Overview

In this ongoing, randomized, phase 3 trial, sotrovimab (a SARS-CoV-2–targeted monoclonal antibody) or placebo was administered to outpatients within 5 days after the onset of Covid-19 symptoms. The incidence of hospitalization for any cause or death was lower among patients who received sotrovimab (1% vs. 7%).

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Adverse events

/ Aged

/ Ambulatory Care

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use